Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN

20 Jun 2023

Abstract excerpt

The TP53 and PTEN tumour suppressor genes are inactivated by nonsense mutations in a significant fraction of human tumours. TP53 nonsense mutatant tumours account for approximately one million new cancer cases per year worldwide. We have screened chemical libraries with the aim of identifying compounds that induce translational readthrough and expression of full-length p53 protein in cells with nonsense mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37339263
DOI: 10.1080/15476286.2023.2222250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTENPMID 37339263Read ↗

Therapeutic targeting of TP53 nonsense mutations in cancerSemantic proximity Read ↗

Novel small molecules potentiate premature termination codon readthrough by aminoglycosides.Semantic proximity Read ↗

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 InhibitorsSemantic proximity Read ↗

Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.Semantic proximity Read ↗

Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-FluorouridineSemantic proximity Read ↗

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.Semantic proximity Read ↗

The antimalarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418Semantic proximity Read ↗

Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.Semantic proximity Read ↗

Readthrough compounds for nonsense mutations: bridging the translational gap.Semantic proximity Read ↗

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potentialSemantic proximity Read ↗

ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease.Semantic proximity Read ↗

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.